Quick Takeaways: Why It Matters? Lenivia strengthens Zoetis’ lead in monoclonal antibody–based pain management for dogs by adding a longer-acting OA option to its portfolio. Market-wise, a single injection providing up to three months of osteoarthritis pain...
Quick Takeaways Why It Matters? Befrena gives Elanco a direct challenger to Zoetis’ Cytopoint in the fast‑growing canine allergy biologics market, with a slightly longer recommended dosing interval (every 6–8 weeks vs 4–8 weeks) and no age or weight limits...
